# US 2021/0275579 A1 · Electrochemically activated salt solution > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0275579 A1 - Document ID: US20210275579A1 - Status: Published application - Kind: A1 - Application number: 17/259,458 - Filed: 2019-07-10 - Published: 2021-09-09 - Earliest claimed: 2018-07-12 - Assignees: Azad Pharma AG - Applicants: AZAD Pharma AG - Inventors: Mihran BARONIAN; Fabio CARLI; Elisabetta CHIELLINI; Ernest BAEHLER - Web page: https://patentgrep.com/patent/US20210275579A1 ## CPC - A61K 33/22: Boron compounds - A61K 9/0048: {Eye, e.g. artificial tears} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine - A61K 33/42: Phosphorus; Compounds thereof - A61P 27/02: Ophthalmic agents - A61P 31/04: Antibacterial agents - A61P 31/10: Antimycotics - A61P 31/12: Antivirals - A61P 31/22: for herpes viruses - C25B 1/26: Chlorine; Compounds thereof (by simultaneous production of alkali metal hydroxides and chlorine, oxyacids or salts of chlorine C25B1/34) - C25B 11/02: characterised by shape or form - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C25B: ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR (anodic or cathodic protection C23F13/00; single-crystal growth C30B) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present application refers to an electrochemically activated salt solution (EGAS), its production, and its use for treating infections. ## Claims ### Claim 1 Electrochemically activated salt solution (ECAS) comprising a content of total chlorine of between 1 and 500 mg/l, preferably 100-450 mg/l, a content of chloride of between 2 and 8 g/l, preferably 3-7 g/l, a redox potential of +150 to +1,350 mV, preferably +600 to +1,100 mV, more preferably +700 to +1,050 mV, more preferably +700 to +1,000 mV, an osmolality of 20-800 mOsm/kg, preferably 200-400 mOsm/kg, more preferably 250-350 mOsm/kg, a pH value of 6.0-7.8, preferably 7.1-7.4, and optionally at least one (salt of) boric acid and/or at least one (salt of) phosphoric acid. ### Claim 2 (depends on 1) Electrochemically activated salt solution (ECAS) according to claim 1, comprising at least one (salt of) phosphoric acid, preferably in an amount of 0.01-1000 g/l, more preferably 0.1-100 g/l. ### Claim 3 (depends on 1) Electrochemically activated salt solution (ECAS) according to claim 1, comprising at least one (salt of) boric acid, preferably in an amount of 0.01 to 1000 g/l more preferably 0.1-500 g/l. ### Claim 4 (depends on 1) Electrochemically activated salt solution (ECAS) according to claim 1, which contains hypochlorite ions and/or hypochlorous acid, particularly in a total concentration of 1 to 10000 mg/l, more preferably in a total concentration of 10 to 1000 mg/l. ### Claim 5 (depends on 1) Electrochemically activated salt solution (ECAS) according to claim 1, further comprising at least one viscosity-increasing agent, such as a polymer, either organic or inorganic. ### Claim 6 (depends on 1) Electrochemically activated salt solution (ECAS) according to claim 1, which does not contain an additional therapeutically active agent, such as a drug. ### Claim 7 (depends on 1) Electrochemically activated salt solution (ECAS) according to claim 1, which does not contain an additional preservative. ### Claim 8 (depends on 1) Pharmaceutical preparation comprising an electrochemically activated salt solution (ECAS) according to claim 1, preferably further comprising at least one pharmaceutically acceptable excipient. ### Claim 9 (depends on 1) Electrochemically activated salt solution (ECAS) according to claim 1 for use in treating infections, preferably eye infections, e.g. caused by bacteria, fungi and/or viruses. ### Claim 10 (depends on 9) Electrochemically activated salt solution (ECAS) for use according to claim 9, wherein the bacteria and/or fungi are selected from the group consisting of Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Escherichia coli, Staphylococcus epidermidis, Pseudomonas aeruginosa, Acinetobacter calcoaceticus, Enterobacter aerogenes, Streptococcus anginosus, Streptococcus pyogenes, Candida albicans, Aspergillus brasiliensis, Serratia marcescens and Acinetobacter pitii. ### Claim 11 (depends on 9) Electrochemically activated salt solution (ECAS) for use according to claim 9, wherein the viruses are selected from the group consisting of adenoviruses, enteroviruses and herpesviruses, such as Herpes simplex virus 1 and 2. ### Claim 12 (depends on 9) Electrochemically activated salt solution (ECAS) for use according to claim 9 in treating conjunctivitis, particularly bacterial conjunctivitis, keratitis, blepharitis, and/or endophthalmitis. ### Claim 13 (depends on 9) Electrochemically activated salt solution (ECAS) for use according to claim 9, which is administered onto the eye, preferably directly after infection. ### Claim 14 (depends on 1) Process for producing an electrochemically activated salt solution (ECAS) according to claim 1 comprising the steps: (i) electrolyzing an aqueous chloride solution in an electrolysis reactor, preferably including a cylindrical cathode, which is mounted coaxially within a cylindrical anode, (ii) optionally adding at least one (salt of) boric acid and/or at least one (salt of) phosphoric acid, and (iii) optionally diluting the ECAS by adding water for injection. ### Claim 15 (depends on 14) Process according to claim 14, wherein the electrolysis is conducted at a current of 10.0-30.0 A, preferably 15.0-20.0 A.